Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events (DECLARE-TIMI58)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01730534
Recruitment Status : Completed
First Posted : November 21, 2012
Last Update Posted : October 2, 2018
Sponsor:
Collaborators:
Bristol-Myers Squibb
The TIMI Study Group
Hadassah Medical Organization
Information provided by (Responsible Party):
AstraZeneca

Results Submitted - Not Posted on ClinicalTrials.gov
Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
Recruitment Status : Completed
Actual Primary Completion Date : September 11, 2018
Actual Study Completion Date : September 11, 2018
Submission Cycle Results Submitted to ClinicalTrials.gov Results Returned after Quality Control Review
1 September 6, 2019
(Canceled on September 6, 2019)
September 9, 2019
October 3, 2019
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):